Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.32 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19244697 | 0.89 | PDE5A (0.33) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14746418 | 0.87 | PDE5A (0.41) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15519721 | 0.85 | PTGDR2 (0.39) | PDE5AGUCY1A1GUCY1B1PTGDR2 | |
| SCHEMBL175275 | 0.85 | PDE5A (0.47) | PDE5AGUCY1A1GUCY1B1PTGDR2 | |
| SCHEMBL19244706 | 0.84 | GRIN1 (0.34) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL19244701 | 0.83 | PTGDR2 (0.40) | PDE5AGUCY1A1GUCY1B1PTGDR2 | |
| SCHEMBL19244708 | 0.83 | PDE5A (0.36) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL19244698 | 0.83 | GRIN1 (0.34) | PDE5AGUCY1A1GUCY1B1 | |
| Acetic Acid SCHEMBL16244961 | 0.83 | PDE5A (0.34) | PDE5AGUCY1A1GUCY1B1RORCPTGDR2 | |
| SCHEMBL9913982 | 0.82 | PDE5A (0.32) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708539-A1 | Annulated pyrimidines and triazines and their use | Bayer Intellectual Property GmbH (DE) | 2014-03-19 | — | — | EP | disclosed |
| EP-2682394-A1 | 1H-pyrazolo[3,4-b]pyridin-triazine derivatives and their use for the treatment or the prevention of cardiovascular diseases | Bayer Intellectual Property GmbH (DE) | 2014-01-08 | — | — | EP | disclosed |